8-K: Vivani Medical Announces Spin-Off of Cortigent and First Implant in GLP-1 Clinical Trial

Vivani Medical is spinning off its Cortigent neurostimulation business and has achieved the first implant and full enrollment in its LIBERATE-1 clinical trial for a GLP-1 implant.

Summary

• Vivani Medical intends to spin off Cortigent, its neurostimulation business, into a separate publicly traded company.
• The spin-off is expected to be completed by Q3 2025, pending board approval, a favorable tax opinion, and regulatory and Nasdaq approval.
• Vivani has successfully administered its first GLP-1 implant in the LIBERATE-1 clinical trial.
• The LIBERATE-1 study has achieved full enrollment just four weeks after the first subject was enrolled.
• Top-line results from the LIBERATE-1 study are expected in mid-2025.
• Vivani had approximately $18.4 million in cash and cash equivalents as of December 31, 2024 (unaudited).

Sentiment

Score: 7

Explanation: The document conveys a moderately positive sentiment due to the progress in clinical trials and strategic moves like the spin-off. However, the forward-looking statements and associated risks temper the overall optimism.

Positives

• The spin-off of Cortigent is expected to create two focused companies, potentially increasing value for shareholders.
• Cortigent's Orion system has shown encouraging safety and efficacy results in an early feasibility study.
• The successful first implant in the LIBERATE-1 trial is a significant milestone.
• Rapid enrollment in the LIBERATE-1 study indicates strong interest in the GLP-1 implant.
• The company expects the GLP-1 implant to improve medication adherence and patient outcomes.
• Vivani anticipates top-line results from the LIBERATE-1 study in mid-2025.

Negatives

• The preliminary financial information is unaudited and subject to change, with actual results potentially differing materially.
• The spin-off is subject to several conditions, including board approval and regulatory approvals, which may not be met.
• The company has a history of losses and may need to access additional capital to fund its business.

Risks

• The spin-off may not be completed in a timely manner or at all.
• The spin-off may not qualify as a tax-free transaction.
• The anticipated benefits of the spin-off may not be achieved.
• Unexpected costs or delays could impact the spin-off and product development.
• Clinical trial results may not be favorable.
• The company may face challenges in developing and commercializing its products.
• The company's ability to access additional capital is uncertain.

Future Outlook

Vivani plans to complete the spin-off of Cortigent by Q3 2025 and expects top-line results from the LIBERATE-1 trial in mid-2025. The company will focus on developing its portfolio of miniature, subdermal GLP-1 implants.

Management Comments

• Vivani expects that Cortigent will continue to be a leader in discovering, developing, and commercializing innovative therapies for vision, stroke recovery and other critical body functions that can benefit from neurostimulation technology.
• Vivani believes that the best way to realize the full potential of Cortigent is to enable it to operate independently with a management team dedicated to advancing its proprietary neuromodulation technology and developing medical devices that address human conditions where there is significant unmet medical need.
• Vivani's mission remains unchanged as it continues to leverage its proprietary NanoPortal implant technology and advance the development of its portfolio of miniature, subdermal GLP-1 implants with once or twice-yearly dosing for chronic weight management, type 2 diabetes, and other chronic diseases.
• Cortigent will intensify its efforts to develop and commercialize life-changing medical devices for people with critical unmet medical needs such as blindness, paralysis due to stroke, and potentially other conditions.
• Vivani believes its miniature, ultra long-acting implants, designed to improve medication adherence, have the potential to improve efficacy and minimize tolerability issues.

Industry Context

The neurostimulation market is experiencing substantial growth, driven by the rising prevalence of chronic diseases and advancements in technology. The GLP-1 market is competitive, with over 50 new molecular entities under clinical stage development. Vivani is positioning its long-acting GLP-1 implants as a differentiated therapeutic option.

Comparison to Industry Standards

• Cortigent's Argus II Retinal Prosthesis System is comparable to other artificial vision devices in development, such as those from Pixium Vision and Nano Retina.
• Vivani's GLP-1 implants aim to address medication adherence issues, a common challenge with existing GLP-1 therapies like Ozempic and Wegovy from Novo Nordisk, and Bydureon BCise from AstraZeneca.
• The company's approach of using a subdermal implant for drug delivery is similar to other companies developing long-acting injectables and implants, such as those from Intarcia Therapeutics (although they faced regulatory challenges).

Stakeholder Impact

• Shareholders may benefit from the increased focus and potential value creation of the two separate companies.
• Patients may benefit from new treatment options for blindness, stroke recovery, chronic weight management, and type 2 diabetes.
• Employees of both Vivani and Cortigent may experience changes in their roles and responsibilities as a result of the spin-off.

Next Steps

• Complete the spin-off of Cortigent by Q3 2025.
• Report top-line results from the LIBERATE-1 study in mid-2025.
• Continue development of NPM-115, NPM-139, and NPM-119.
• Pursue regulatory approvals for the company's products.

Key Dates